comorbidity [4] . Given the potential impact of these untreatable disorders in aging CART-treated populations, understanding, predicting, and preventing them is important. Although host factors have been associated with HAND [4, 5] , genetic predictors of HAND should be more thoroughly characterized.
Early studies of HAND genetics examined HIV-associated dementia (HAD), AIDS dementia complex, or HIV-associated encephalitis, phenotypes that are uncommon in the CART era, and identified associations with chemokine coreceptor 5 (CCR5) [6] and apolipoprotein E (ApoE) [7] gene variants. Recent analyses have included milder NCI phenotypes and have continued to primarily examine the ApoE ε4 allele, with inconsistent results [8, 9] . Reviews on this topic provide additional background and highlight the limitations of relatively small sample sizes and heterogeneous phenotypes [10] . One genome-wide association study (GWAS) of HAND has been reported in a sample of 1287 adults of predominantly European ancestry enrolled in the Multicenter AIDS Cohort Study [11] . This analysis did not find associations meeting GWAS-level significance (P < 5 × 10 -8 ) but did identify associations between processing speed and 2 single-nucleotide polymorphisms (SNPs) in ion channel transporters (SLC8A1 and NALCN) that approached statistical significance. The critical and complex roles of mitochondria in energy production, reactive oxygen species (ROS) homeostasis, and apoptotic regulation make them vulnerable targets and key mediators of cellular damage in response to environmental stresses. Given high-energy demands of the central nervous system (CNS), mitochondrial function is critically important in neuronal function and neurodegenerative diseases. Mitochondrial DNA (mtDNA) is maternally inherited and encodes 13 electron transport chain polypeptides. Patterns of mtDNA variantshaplogroups-define maternal ancestry, may influence successful aging, and have been associated with human diseases [12] . The potential importance of mtDNA variation in NCI is supported by the prominence of neurologic phenotypes in inherited mtDNA diseases and associations between mtDNA haplogroups and neurodegenerative diseases [13] . Several studies have reported associations between mtDNA haplogroups and HIV-or CART-associated outcomes, including peripheral neuropathy and neuroretinal disease [14] . Furthermore, haplogroup-defining mtDNA variants have recently been linked to altered expression of inflammation, complement, and apoptosis genes, raising the possibility that mitochondrial-nuclear interactions play a role in immune regulation [15] .
We hypothesized that genetic variation in mtDNA modulates susceptibility to or severity of NCI in HIV infection, perhaps through neuroinflammation. There are data in HIV-uninfected populations supporting a link between mitochondrial dysfunction and neuroinflammation in neurodegenerative processes [16] , and associations with these diseases and mtDNA variation cited above provide indirect evidence for this hypothesis. This link is yet to be established in HAND. Characterizing associations between mtDNA haplogroups and NCI in this population may facilitate risk stratification of patients and identify targets for prevention or therapy. Because studies of the role of mtDNA haplogroups in HAND have not been published, we used stored DNA and cross-sectional data from the CHARTER study to address this question, and present the first report of a genetic association.
METHODS
Where appropriate, methods followed recommendations from the STrengthening the Reporting of Genetic Association Studies Statement (Supplementary Table 1 ) [17] .
Study Design and Participants
CHARTER is a prospective, observational study conducted at 6 US locations: Baltimore, Maryland; New York, New York; San Diego, California; Galveston, Texas; Seattle, Washington; and St Louis, Missouri. Institutional review boards at each site approved this research, and each participant provided written informed consent. Data were collected between 2003 and 2007 according to a protocol of comprehensive neuromedical, neurobehavioral, and laboratory assessments that were standardized across sites [4] . The data reported herein are a crosssectional genetic association analysis of a subgroup of CHAR-TER participants.
Assessments of Neurocognitive Impairment
Participants were English-speaking and underwent a comprehensive test battery that included seven neurocognitive domains affected by HIV-associated CNS dysfunction [4] . Composite global deficit score (GDS) was derived from standard T-scores using best available normative standards to correct for learning, age, education, sex, and ethnicity, as appropriate. For selfreported Hispanics, 3 of 15 measures were corrected for English-speaking Hispanic normative standards; the remainder was adjusted for Caucasian normative standards [18, 19] . The GDS as a continuous variable reflects the number and severity of neurocognitive deficits across the battery; it is the average of the deficit scores on each test, where T ≥ 40 = 0 (no deficit), 35-39 = 1(mild deficit), 30-34 = 2 (mild to moderate deficit); 25-29 = 3 (moderate deficit), 20-24 = 4 (moderate to severe deficit), and <20 = 5 (severe deficit). An established cutoff of GDS ≥ 0.50 defines NCI [20] . To further classify presence and severity of HAND, we applied a published objective algorithm that has been shown to yield excellent inter-rater reliability in previous multisite studies [21] . This algorithm conforms to the Frascati criteria for diagnosing HAND [22] , requiring at least mild impairment in ≥2 of seven domains, and includes functional assessment by self-report or performance-based criteria or both, as well as exclusions based upon comorbidities (non-HIV related risks for NCI). Categories of HAND include asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HAD. Standardized assessments were performed by physicians, nurse practitioners, or trained nurses and research associates certified by the CHAR-TER coordinating center. As described previously [4] , HAND categorization required a determination that NCI and functional impairment were likely due to HIV-related effects on the brain rather than comorbid conditions. Detailed review by 2 senior CHARTER investigators using published guidelines [22] provided categorization of comorbid conditions for all CHARTER participants as incidental, contributing, and confounding. Several conditions (eg, brain trauma, epilepsy or other seizure history, CNS opportunistic diseases) informed this categorization; detailed information on their frequencies are presented elsewhere [4] . Individuals with confounded neurocognitive comorbidities (15% of the total CHARTER cohort) that precluded an assessment of the contribution of HIV to their NCI were not eligible for a diagnosis of HAND according to Frascati criteria [4, 22] and were excluded from genetic analyses.
Mitochondrial DNA Sequencing and Haplogroup Determination
Isolation of DNA from whole blood samples was performed using PUREGENE (Gentra Systems Inc, Minneapolis, Minnesota ). Full mtDNA sequencing was performed using the GeneChip Human Mitochondrial Resequencing Array v2.0 (Affymetrix, Inc, Santa Clara, California).
Array intensity data were processed using the MitoChip Filtering Protocol [23] , and variants were called relative to the Revised Cambridge Reference Sequence [24] , Haplogroups were assigned using HaploGrep (http://haplogrep.uibk.ac.at/) [25] .
Most participants also underwent nuclear DNA genotyping using the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Inc, Santa Clara, California). Ancestry-informative markers were analyzed using EIGENSTRAT software [26] to generate principal components (PC) (Supplementary Figure 1) . Model-based clustering on the top 3 PCs, using the mclust R package, was used to assign individuals to genetic ancestry clusters using an ellipsoidal model [27] . Genetic ancestry clusters showed 97.4% agreement with self-reported race and ethnicity (Supplementary Table 2 ). All analyses used PC-ancestry based stratifications (European, African, or admixed Hispanic).
Statistical Analyses
Three outcomes were analyzed: (1) Continuous GDS; (2) dichotomous NCI (defined as GDS ≥ 0.50) vs no impairment (GDS < 0.50); and (3) HAND (any HAND category vs normal) [22] . Prior research has shown strong agreement between the latter 2 methods of classifying NCI, such that NCI by GDS criteria virtually guarantees the presence of HAND, but a minority of HAND cases are classified as within normal limits by the GDS [20] . Primary analyses were stratified by PC-derived genetic ancestry. Univariate analyses included nonparametric Wilcoxon tests for continuous variables and Fisher exact tests for dichotomous variables. Multivariable regression of associations between mtDNA haplogroups and GDS and HAND were adjusted for: comorbidity status (incidental vs contributing); current CART use (yes vs no); plasma HIV RNA; reading ability (by Wide-Range Achievement Test-III [WRAT] Reading subtest score); and self-reported nadir CD4 + T-cell count.
Adjustments for multiple comparisons were not performed given the exploratory nature of these analyses, the limited number of exposure (genetic) variables within stratified groups, and the relatively limited number of outcomes assessed. Statistical analyses were conducted using R (version 2.15.1) and Stata Statistical Software, Release 13 (College Station, Texas: StataCorp LP).
RESULTS

Participant Characteristics
Haplogroups were available from 1068 participants. Of these, 1027 (96%) had nuclear DNA genotypes that allowed for PC assessment of genetic ancestry (Supplementary Figure 2) . The median age for the analysis group (Table 1) was 43 years, median CD4 + T-cell nadir was 178 cells/mm 3 , 736 (72%) were on CART at initial assessment, 474 (46%) had HAND, and the median (interquartile range [IQR]) GDS was 0.32 (0.11-0.63). Haplogroup frequencies within each ancestry category were consistent with US population based data [28] (Supplementary Table 3 ) and did not differ across CHARTER sites (data not shown).
Univariate Analyses of Global Deficit Score and HIV-associated Neurocognitive Disorders
Persons of admixed Hispanic ancestry had a higher median (IQR) GDS (0.53; 0.21-0.94) than persons of African (0.26; 0.11-0.53; P < .0001) or European (0.37; 0.16-0.68; P = .003) ancestry (Supplementary Figure 3A) . Persons of admixed Hispanic ancestry also had a greater likelihood of either impaired GDS (52% vs 29% African [P < .0001] and 37% European [P = .009]; Supplementary Figure 3B Median GDS did not differ significantly by mtDNA haplogroup in participants of African or European ancestry (Figure 1A and 1B) . Among the 102 persons of admixed Hispanic ancestry, WRAT-III, GDS, and percentage with GDS impairment or HAND differed significantly across haplogroups in univariate analyses (Table 1) . Persons belonging to haplogroup B (N = 20; 20%) had a lower median GDS (0.21 vs 0.63; P = .002; Figure 1C and 
Multivariate Analyses of Global Deficit Score and HIV-associated Neurocognitive Disorders
In adjusted models of persons of admixed Hispanic ancestry, haplogroup B was associated with a lower GDS (β = −0.34; −0.59, −0.09; P = .008; Table 5) .
DISCUSSION
In this analysis of chronically HIV-infected, mostly CARTtreated CHARTER participants, persons of Hispanic ancestry had more NCI overall, but a common mtDNA haplogroup within the population was associated with significantly lower prevalence of NCI. Specifically, among the almost 20% of persons of admixed Hispanic ancestry having mtDNA haplogroup B, median GDS and the proportion with impaired GDS were significantly lower than in persons with other haplogroups after adjustment for potential confounders. Mitochondrial DNA variants, including haplogroups, have been studied in relation to neurodegenerative diseases in HIV-negative populations. Several studies have explored host genetic risks for HIV-associated NCI [10] and associations between mtDNA haplogroups and non-CNS HIV-related outcomes [14] . This is the first analysis to our knowledge of mtDNA variation and NCI in an HIV-infected population. Haplogroup B is a major haplogroup seen in persons of East Asian, Native American, and admixed Hispanic ancestry [29, 30] , is part of the R superhaplogroup, and includes variations common to the related European haplogroups J and T [31] (Supplementary Figure 4) . Haplogroup B has been associated with nonneurocognitive phenotypes in recent studies [32, 33] . The B haplogroup was also recently associated with changes in epidermal nerve fiber density (ENFD, a measure of small fiber neuropathy) in lower extremity skin biopsies from HIVinfected persons starting CART as part of a clinical trial in Thailand [34] . In that study, persons with the B haplogroup had an increase in ENFD and plasma 8-oxo-deoxyguanosine (a marker of oxidative DNA damage also associated with HAND and mtDNA damage in brain tissue [35] ) on CART. Our data cannot address apparently discrepant associations between haplogroup B and what may be an adverse peripheral nerve phenotype in HIV-infected Thais and less NCI in US Hispanics. A recent publication reported an association between subhaplogroup B5a and increased risk for Alzheimer's disease in Han Chinese [36] . Lymphoblastoid and HeLa cells harboring haplogroup B5a and a nonsynonymous SNP (m.8584G > A) found in B5a, respectively, demonstrated adverse mitochondrial phenotypes compared to control cells. Importantly, although B5 was the predominant subhaplogroup in this Han Chinese population and the study of HIV-infected Thais [34] , B5 is not represented in our population of admixed Hispanics from the United States. We speculate that this population-specific subhaplogroup could determine whether the B haplogroup is associated with neurodegeneration or neuroprotection.
Potential mechanisms by which mtDNA variation could alter susceptibility to NCI would be similar to those posited for other neurodegenerative processes in aging populations, including differences in ROS production, oxidative stress, inflammation, and apoptotic regulation. In chronic HIV infection, systemic or CNS inflammation or both may contribute to NCI. Given the role of mitochondria in inflammatory processes [37] , mtDNA variation could be an additional susceptibility factor. A potential confounder in this population is exposure to older mitochondria-toxic CART drugs, particularly "d-drug" NRTIs zalcitabine, didanosine, or stavudine. Among these CHARTER participants, 13% were taking 1 or more of these at enrollment; 39% had a history of exposure. In secondary multivariate models, neither d-drug exposure at enrollment nor past exposure were associated with NCI in the admixed Hispanic population, and associations between mtDNA haplogroup B did not change substantially (data not shown). There tended to be variability in the duration of CART exposure by haplogroup among the admixed Hispanic population (Table 1) . We therefore also performed a secondary model adjusting for CART duration, and did not observe substantial differences in the haplogroup B results (data not shown).
A strength of our study is the well-characterized and racially and geographically diverse population with NCI and HAND diagnoses and confounders identified in a standardized fashion. Limitations include those inherent to cross-sectional analyses and the lack of an HIV-uninfected control population. Longitudinal approaches to NCI in CHARTER have recently been published [2, 3] , and genetic analyses of longitudinal changes in NCI are needed. Although this analysis includes an overall large sample, numbers of persons from minority genetic ancestry groups and within individual mtDNA haplogroups are relatively small. The small sample size of adults of admixed Hispanic ancestry suggests that although the effect sizes identified were large enough to reach statistical significance, the findings may not generalize to other populations of HIV-infected adults of Hispanic ancestry. We did not observe statistically significant associations between mtDNA haplogroup and NCI or HAND in persons of European or African genetic ancestry in CHARTER. Despite relatively large sample sizes, our analyses may be underpowered to detect small but potentially clinically relevant differences, or that subhaplogroups or mtDNA variants not specifically included in our analysis are associated with NCI. The relevance of ANI, the most common HAND category in this population, has been questioned [38] . Recent data, however, have demonstrated that persons with ANI are at risk for symptomatic decline, supporting its clinical and prognostic value [3] . We performed sensitivity analyses of the HAND outcome in admixed Hispanic participants excluding those with ANI (ie, comparing neurocognitively normal vs MND or HAD). With this smaller population (N = 54), the adjusted OR for the B haplogroup was of a similar direction and magnitude (0.22), with an increase of P-value from .08 to .14.
Utility of standardized NCI measures in persons of nonEuropean ancestry is less well established, an important consideration given that we observed both greater prevalence of and haplogroup associations with NCI only in the admixed Hispanic ancestry population. Because specific Hispanic neurocognitive norms exist for only 3 of the tests in the CHARTER battery, use of Caucasian norms for the other tests may have contributed to higher rates of impairment among Hispanics. The choice of norms was based upon evidence that performance of US Hispanics on multiple neurocognitive tests is closer to that of Caucasian than African Americans [39] .
In addition, recent longitudinal CHARTER analyses found self-reported Hispanic ethnicity to be a risk factor for decline in neurocognitive performance from baseline over a mean of 36 months of follow-up [2] ; those analyses did not use crosssectional neurocognitive norms and also found Hispanic ethnicity to be associated with NCI. Although self-identified Hispanic participants were drawn from CHARTER sites across the United States, haplogroup frequency did not differ significantly across sites, and the B haplogroup was associated with NCI independent of WRAT-III, a measure of premorbid intelligence and quality of educational background. In addition, birthplace (US or Canada vs other) and primary language (English vs other) did not differ significantly between B and other haplogroups among participants of admixed Hispanic ancestry (data not shown), but there may be other unmeasured or unknown biologic or sociodemographic confounders associated with both mtDNA haplogroup and NCI. Due to genetic diversity and admixture of persons of selfidentified Hispanic-American ethnicity, genotype-phenotype associations are complex [40] , and definitive conclusions must be drawn cautiously and only after replication.
Future analyses should examine associations between haplogroups and CSF neuroinflammation and non-haplogroupdefining SNPs and NCI, and interactions between mtDNA variants and SNPs in nuclear genes relevant for mitochondrial function and inflammation. Prospective studies may also explore targeted genetic testing for risk-stratification and personalized interventions. Should this association be validated, mtDNA variation may be a novel, ancestry-specific host factor influencing HAND in chronically HIV-infected persons and may provide pathogenic clues that will lead to a better understanding of this condition.
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